Hepatitis Treatment Market Outlook, Segmentation, Growth Drivers and Competitor Analysis – 2023

A new market study, titled “Hepatitis Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023”, has been featured on WiseGuyReports.

Hepatitis Treatment Market: By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, Others), By Drug Type (Vaccines, Anti-Viral Drugs, Interferons, Others), By Route of Administration (Oral , Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Market Outline: Hepatitis Treatment Market

Hepatitis is the disease characterized by the inflammation of the liver. Hepatitis mainly occur due to the viral infections, heavy alcohol intake, consumption of hepatotoxic drugs, blood transfusions and autoimmune diseases among others. Hepatitis is classified as hepatitis A, B, C, D, E in which hepatitis A, B, C mostly occurs in humans. The symptoms associated with hepatitis include poor appetite, whites of eyes, discoloration of skin, vomiting, abdominal pain, and diarrhoea among others. Hepatitis can be prevented by the administration of vaccines in newborn babies.

Market Dynamics: Hepatitis Treatment Market

Increase in the incidence of different types of hepatitis infections, the rise in R&D activities for the development of newer drugs and vaccines, government initiations for the prevention of hepatitis, promising pipeline products for the hepatitis treatment are anticipated to fuel the hepatitis treatment market over the forecast period. Moreover, the rise in awareness about hepatitis treatment options among key stakeholders, increase in the consumption of alcohol, and high usage of hepatotoxic drugs and other toxins are expected to propel the hepatitis treatment market over the forecast period. However, stringent regulatory policies for the product approval, lack of vaccines for certain types hepatitis such as hepatitis C, and the high cost of the treatment are expected to hinder the growth of hepatitis treatment market over the forecast timeframe.

View Detailed Report at https://www.wiseguyreports.com/reports/2984799-hepatitis-treatment-market-global-market-estimation-dynamics-regional

Market Scope: Hepatitis Treatment Market

Hepatitis treatment market is segmented on the basis of disease type, drug type, route of administration, distribution channel, and region

Based on disease type, the market is segmented into the following

Hepatitis A

Hepatitis B

Hepatitis C

Hepatitis D

Hepatitis E

Others

Based on the drug type, the market is segmented into the following:

Vaccines

Anti-Viral Drugs

Interferons

Others

Based on the route of administration, the market is segmented into the following:

Oral

Parenteral

Based on the distribution channel, the market is segmented into the following:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Based on the region, the market is segmented into the following:

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

Request Sample Report at https://www.wiseguyreports.com/sample-request/2984799-hepatitis-treatment-market-global-market-estimation-dynamics-regional

Market Summary: Hepatitis Treatment Market

Global hepatitis treatment market is driven by rising in the prevalence of various types of hepatitis infections. According to WHO in 2015, approximately 257 Mn hepatitis B, 71 Mn hepatitis C cases, and approximately 15 Mn hepatitis D cases observed around the globe. Majority of the local and international market players are actively seeking to develop newer drugs and vaccines for the treatment of hepatitis infection. Moreover, strong product pipeline for hepatitis treatment expected to upsurge the market revenue over the forecast timeframe. Furthermore, acquisitions and mergers, product approvals, and product launchings are the strategies adopted by the market players for dominating the hepatitis treatment market. For instance, in June 2016, FDA approved Epclusa manufactured by Gilead Sciences, Inc. used in the treatment of chronic hepatitis C virus infection. Moreover, in May 2017, Eiger Biopharmaceuticals filed investigational new drug application with FDA for Lambda (pegylated interferon lambda 1a) for the treatment of hepatitis D.

Regional Analysis: Hepatitis Treatment Market

Geographically, global hepatitis treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America hepatitis treatment market is poised to grow due to increase in the prevalence of hepatitis infection, the rise in R&D activities for the innovation of new drugs, an increase in healthcare expenditure in the region. Europe hepatitis treatment market expected to exhibit lucrative growth owing to rise in prevalence of hepatitis due to change in lifestyle, increase in awareness about the hepatitis treatment, and adoption of newer drugs and vaccines are propelling the market. Asia Pacific hepatitis treatment market is growing due to increase in the geriatric population in India, China, and Japan, the rise in healthcare expenditure, and launching of generic drugs into the market. Latin America hepatitis treatment market is driven by an increase in hepatitis C infection, launching of newer products into the market, and increase in the awareness about hepatitis treatment. Middle East and Africa hepatitis treatment market’s growth is attributed to economic growth, increase in the prevalence of hepatitis infection in African countries, and expansion of businesses by market players in the region.

Competition Assessment: Hepatitis Treatment Market

Some of the players in the global hepatitis treatment market include:

Hoffmann- La Roche Ltd. (Switzerland)

Gilead Sciences (U.S.)

Novartis AG (Switzerland)

Bristol-Myers Squibb (U.S)

GlaxoSmithKline, plc.

Merck and Co, Inc. (U.S)

Johnson & Johnson Services, Inc. (U.S.)

AbbVie Inc. (U.S.)

Novira Therapeutics Inc. (U.S.)

Eiger Biopharmaceuticals (U.S.)

Notable Market Developments: Hepatitis Treatment Market

In September 2017, China Food and Drug Administration approved Gilead’s Sovaldi (Sofosbuvir) used in the treatment of chronic HCV infection

 

Table of Content

1. Executive Summary
2. Global Hepatitis Treatment Market Introduction
3. Global Hepatitis Treatment Market Dynamics
4. Global Hepatitis Treatment Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023
5. Global Hepatitis Treatment Market, By Disease Type, 2012 – 2016 and Forecast, 2017 – 2023
6. Global Hepatitis Treatment Market Forecast, By Drug Type, 2012 – 2016 and Forecast, 2017 – 2023
7. Global Hepatitis Treatment Market Forecast, By Route of Administration, 2012 – 2016 and Forecast, 2017 – 2023
8. Global Hepatitis Treatment Market Forecast, By Distribution Channel, 2012 – 2016 and Forecast, 2017 – 2023
9. Global Hepatitis Treatment Market Forecast, By Region, 2012 – 2016 and Forecast, 2017 – 2023
10. North America Hepatitis Treatment Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023
11. Europe Hepatitis Treatment Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023
12. Asia-Pacific Hepatitis Treatment Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023
13. Latin America Hepatitis Treatment Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023
14. Middle East and Africa Hepatitis Treatment Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023
15. Competition Landscape
16. Research Methodology
17. Key Assumptions and Acronyms

 

About Us:

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

 

Contact Us:

NORAH TRENT                                                      

sales@wiseguyreports.com       

Ph: +1-646-845-9349 (US)                          

Ph: +44 208 133 9349 (UK)